行情

ADMS

ADMS

Adamas Pharma
NASDAQ

实时行情|Nasdaq Last Sale

5.57
-0.03
-0.54%
交易中 12:53 11/14 EST
开盘
5.60
昨收
5.60
最高
5.71
最低
5.46
成交量
16.84万
成交额
--
52周最高
12.57
52周最低
3.350
市值
1.55亿
市盈率(TTM)
-1.3819
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMS 新闻

  • 美联储主席鲍威尔:美国经济面临严重萧条的风险不大
  • 新浪财经.19分钟前
  • 鲍威尔对经济增长表达坚定信心 称几乎没有脱轨风险
  • 新浪美股.20分钟前
  • 美联储威廉姆斯:利率处于适当水平 不会进一步降息
  • 新浪美股.22分钟前
  • 午盘:关注鲍威尔国会证词 美股继续走低
  • 新浪美股.53分钟前

更多

所属板块

生物技术和医学研究
-0.17%
制药与医学研究
-0.53%

热门股票

名称
价格
涨跌幅

ADMS 简况

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
展开

Webull提供Adamas Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。